Comparison of weekly and 3-weekly schedule of docetaxel as second line treatment of advanced non-small-cell lung cancer (NSCLC): A meta-analysis of individual data from 818 patients

被引：0
|
作者：
Di Maio, M.
Perrone, F.
Chiodini, P.
Gallo, C.
Camps, C.
Quoix, E.
Schuette, W.
Gridelli, C.
机构：
[1] Ist Nazl Tumori, Unita Sperimentaz Clin, Naples, Italy
[2] Seconda Univ Napoli, Dipartimento Med Pubbl Clin & Prevent, Naples, Italy
[3] Hosp Gen Univ, Valencia, Spain
[4] Hop Lyautey, Strasbourg, France
[5] Martha Maria City Hosp Halle Doelau, Halle, Germany
[6] Azienda Osped S Giuseppe Moscati, Avellino, Italy
来源：
ANNALS OF ONCOLOGY | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：XI25 / XI25
页数：1
相关论文
共 50 条
  • [1] Weekly versus 3-weekly docetaxel as second line chemotherapy for advanced non-small-cell lung cancer (NSCLC): Meta-analysis of phase III trials
    Bria, Emilio
    Cuppone, Federica
    Ciccarese, Mariangela
    Carlini, Paolo
    Nistico, Cecilia
    Natoli, Guido
    Nuzzo, Carmen
    Terzoli, Edmondo
    Cognetti, Francesco
    Giannarelli, Diana
    ANNALS OF ONCOLOGY, 2006, 17 : 223 - 223
  • [2] Does weekly docetaxel improve survival over 3-weekly as second line chemotherapy for advanced non-small-cell lung cancer (NSCLC)? Meta-analysis of phase III trials
    Bria, E.
    Cuppone, F.
    Ciccarese, M.
    Carlini, P.
    Nistico, C.
    Natoli, G.
    Nuzzo, C.
    Terzoli, E.
    Cognetti, F.
    Giannarelli, D.
    ANNALS OF ONCOLOGY, 2006, 17 : XI19 - XI19
  • [3] Can advanced non-small-cell lung cancer be treated with weekly instead of 3-weekly docetaxel?
    Giorgio V Scagliotti
    Nature Clinical Practice Oncology, 2006, 3 : 294 - 295
  • [4] Can advanced non-small-cell lung cancer be treated with weekly instead of 3-weekly docetaxel?
    Scagliotti, G. V.
    NATURE CLINICAL PRACTICE ONCOLOGY, 2006, 3 (06): : 294 - 295
  • [5] Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel
    Schuette, W
    Nagel, S
    Blankenburg, T
    Lautenschlaeger, C
    Hans, K
    Schmidt, EW
    Dittrich, I
    Schweisfurth, H
    von Weikersthal, LF
    Raghavachar, A
    Reissig, A
    Serke, M
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (33) : 8389 - 8395
  • [6] Weekly docetaxel as second line chemotherapy for advanced non-small-cell lung cancer: Meta-analysis of randomized trials
    Bria, Emilio
    Cuppone, Federica
    Ciccarese, Mariangela
    Nistio, Cecilia
    Facciolo, Francesco
    Milella, Michele
    Izzo, Fiorentino
    Terzoli, Edmondo
    Cognetti, Francesco
    Giannarelli, Diana
    CANCER TREATMENT REVIEWS, 2006, 32 (08) : 583 - 587
  • [7] Weekly docetaxel as a second-line treatment for advanced non-small cell lung cancer (NSCLC).
    García, R
    Pérez, P
    Alfonso, R
    Pérez-Manga, G
    Díaz-Rubio, E
    ANNALS OF ONCOLOGY, 2000, 11 : 116 - 116
  • [8] Weekly docetaxel (D) as second line therapy in advanced non small cell lung cancer (NSCLC)
    Valerio, M. R.
    Vizzini, L.
    Intrivici, C.
    Spinnato, F.
    Di Fede, G.
    Rinaldi, G.
    Benfante, B.
    Russo, A.
    Gebbia, N.
    ANNALS OF ONCOLOGY, 2005, 16 : 165 - 165
  • [9] WEEKLY PACLITAXEL VERSUS THE STANDARD 3-WEEKLY SCHEDULE IN PATIENTS WITH NON-SMALL CELL LUNG CANCER
    Halim, I. Abdel
    El-Ashry, M.
    El-Sadda, W.
    Temraz, S.
    ANNALS OF ONCOLOGY, 2012, 23 : 398 - 398
  • [10] Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC)
    Gervais, R
    Ducolone, A
    Breton, JL
    Braun, D
    Lebeau, B
    Vaylet, F
    Debieuvre, D
    Pujol, JL
    Tredaniel, J
    Clouet, P
    Quoix, E
    ANNALS OF ONCOLOGY, 2005, 16 (01) : 90 - 96
12345